Advertisement
The Medicine Maker / Issues / 2017 / Jun / Smashing the Stigma with Science
Manufacture Business & Trends Regulation & Standards Small Molecules

Smashing the Stigma with Science

Cannabis can be a turn off for investors, but Neil Mahapatra and his investment firm are showing the world that there’s nothing to fear – and much to potentially gain – through a collaboration with Oxford University.

By Neil Mahapatra, Stephanie Vine 06/21/2017 1 min read

Share

A Career in Cannabinoids Cannabis Complex Smashing the Stigma with Science A View From the Biosynthetic Bridge Forming a Society for Cannabinoids Enhancing Endocannabinoid Signalling

About the Author(s)

Neil Mahapatra

Neil Mahapatra is Managing Partner of UK investment firm Kingsley Capital Partners, which established Oxford Cannabinoid Technologies in conjunction with a large-scale research programme with Oxford University.

More Articles by Neil Mahapatra

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

Advertisement

Recommended

Advertisement

Related Content

What Trump’s Latest Moves Mean for the Industry
Interviews Bioprocessing Business & Trends
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

FDA to Phase Out Animal Testing
Regulation & Standards Business & Trends Development & Clinical
FDA to Phase Out Animal Testing

April 11, 2025

2 min read

FDA to phase out mandatory animal testing with human-relevant methods for drug development

Coming Soon: the Power List
Cell & Gene Small Molecules
Coming Soon: the Power List

April 11, 2025

2 min read

The 2025 Power List will be available soon!

Partnerships To Be Precise
Outsourcing Business & Trends
Partnerships To Be Precise

April 11, 2025

3 min read

In the ever volatile, highly regulated precision medicine development sector, the agility and expertise of a CDMO can make or break a commercial drug candidate.

Advertisement